Impact of Continuous Venovenous Haemofiltration on Organ Failure During the Early Phase of Severe Sepsis - Full Text View

Purpose

The impact of continuous veno-venous haemofiltration (CVVH) on sepsis-induced multiple organ failure severity is controversial. We thus sought to assess the effect of early application of haemofiltration on the degree of organ dysfunction and plasma cytokine levels in patients with severe sepsis or septic shock.

Condition	Intervention	Phase
Bacteremia Gram-Negative Bacterial Infections Gram-Positive Bacterial Infections Pneumonia, Bacterial Shock, Septic Sepsis	Procedure: venovenous hemofiltration	Phase IV

MedlinePlus related topics:

Bacterial Infections Pneumonia Sepsis

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Supportive Care, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Official Title:	Phase 4 Randomized Multicentric Controlled Study on Impact of Continuous Venovenous Hemofiltration on Organ Failure at the Early Phase of Severe Sepsis

Further study details as provided by Hopital Lariboisière:

Primary Outcome Measures:

The primary end-point was the number, severity and duration of organ failures at 14 days, as evaluated by the SOFA score, on an intention-to-treat analysis

Secondary Outcome Measures:

Secondary end point : safety, ventilation and hemodynamic support weaning

Estimated Enrollment:	400
Study Start Date:	March 1997
Estimated Study Completion Date:	December 1999

Detailed Description:

prospective, randomized, open, multicentre study was performed between 1997 and 1999 in 16 French intensive care units. Patients were enrolled within 24 hours of development of the first organ failure related to a new septic insult. They were randomized to group 1 (HF), who received haemofiltration for a 96 hr period, or group 2 (C) who were managed conventionally. The primary end-point was the number, severity and duration of organ failures at 14 days, as evaluated by the SOFA score, on an intention-to-treat analysis. Strict guidelines were provided to perform continuous haemofiltration under the same conditions and objectives in all centres.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

clinically identified focus of infection associated with at least 2 SIRS criteria and one or more sepsis-induced organ failures within the 24 hours prior to inclusion, plus a SAPS II score between 35-63

Exclusion Criteria:

Patients were excluded if pregnant, younger than 18 years, in a moribund state, in chronic renal failure, or receiving immunosuppressive therapy.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00406198

Locations


France
	Lariboisiere University Hospital
	Paris, France

Sponsors and Collaborators

Hopital Lariboisière

Ministry of Health, France

Investigators


Principal Investigator:	Didier Payen, MD, PhD	Hpopital Lariboisiere

More Information

Study ID Numbers:	DP 97 02 06, ministère recherche EA 322
First Received:	November 30, 2006
Last Updated:	December 1, 2006
ClinicalTrials.gov Identifier:	NCT00406198
Health Authority:	France: Afssaps - French Health Products Safety Agency

Keywords provided by Hopital Lariboisière:

Sepsis syndrom

severe sepsis

septic shock

hemofiltration

multiple organ failure

Study placed in the following topic categories:

Bacterial Infections

Systemic Inflammatory Response Syndrome

Bacteremia

Gram-Negative Bacterial Infections

Inflammation

Sepsis

Gram-Positive Bacterial Infections

Respiratory Tract Infections

Respiratory Tract Diseases

Shock

Pneumonia, Bacterial

Multiple Organ Failure

Lung Diseases

Shock, Septic

Pneumonia

Additional relevant MeSH terms:

Communicable Diseases

Pathologic Processes

Infection

ClinicalTrials.gov processed this record on August 29, 2008

Sponsors and Collaborators:	Hopital Lariboisière Ministry of Health, France
Information provided by:	Hopital Lariboisière
ClinicalTrials.gov Identifier:	NCT00406198